16q22.1 microdeletion and anticipatory guidance

Area of Science:

• Genetics
• Genomic Medicine
• Clinical Genetics

Background:

• Comparative genomic hybridization (CGH) array analysis is increasingly used to identify genomic alterations.
• Microdeletion syndromes are associated with various clinical features, often presenting as unexplained developmental issues.
• Previous studies have linked genomic microdeletions to specific syndromes and patient phenotypes.

Purpose of the Study:

• To report on four unrelated patients with shared clinical characteristics.
• To identify the genetic cause of their unexplained clinical features using CGH array analysis.
• To describe the clinical features associated with a 16q22.1 microdeletion and suggest management guidelines.

Main Methods:

• Utilized comparative genomic hybridization (CGH) array analysis.
• Analyzed genomic DNA from four unrelated patients presenting with similar clinical phenotypes.
• Correlated identified microdeletions with observed clinical features.

Main Results:

• All four patients exhibited a de novo microdeletion at the 16q22.1 locus.
• The patients shared common clinical characteristics including failure to thrive, developmental delay, dysmorphic features, and congenital anomalies.
• The 16q22.1 microdeletion is proposed as the genetic cause for the observed phenotypes.

Conclusions:

• The 16q22.1 microdeletion is associated with a distinct phenotype including failure to thrive, developmental delay, dysmorphic features, and congenital anomalies.
• CGH array analysis is effective in diagnosing microdeletion syndromes.
• Guidelines for managing patients with 16q22.1 microdeletion can be developed based on observed phenotypes and gene functions.